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available online xxxTransjugular intrahepatic portosystemic shunt (TIPS) is increasingly used worldwide to treat the com-
plications of portal hypertension in patients with advanced cirrhosis. However, its use is hampered by
the risk of causing hepatic encephalopathy and of worsening liver function. The reported haemodynamic
targets used to guide TIPS are too narrow to be achieved in most cases and are perhaps not entirely
adequate nowadays as they were obtained in the pre-covered stent era. We propose that small diameter
TIPS – alone or combined to pharmacological therapy or ancillary interventional radiology procedures –
may overcome these limitations while maintaining the beneficial effects of the procedure.
© 2020 European Association for the Study of the Liver. Published by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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https://doi.org/10.1016/
j.jhep.2020.09.018Transjugular intrahepatic portosystemic shunt
(TIPS) is almost universally used to treat portal
hypertension and its complications when they are
not responding to recommended medical therapy,
as well as being used in some special situations.1,2
The most frequent indications for TIPS are
currently recurrent variceal bleeding, treatment of
acute variceal bleeding in high-risk patients, diffi-
cult to treat and refractory ascites, severe portal
hypertensive gastropathy, hepatic hydrothorax,
portal vein thrombosis and Budd-Chiari
syndrome.3
From a functional perspective, TIPS is a “cali-
brated” side-to-side portacaval shunt (like the
“H-graft” surgical shunt).4,5 One potential advan-
tage of TIPS is that it may have less of an effect on
liver perfusion because it is constructed in a portal
vein branch rather than in the mesenteric vein (as
it is in H-graft shunts). As a calibrated shunt, the
aim of TIPS is to sufficiently reduce the portacaval
pressure gradient (PCG) in order to effectively
correct portal hypertension, while (hopefully)
maintaining sufficient portal liver perfusion to
avoid the development of hepatic encephalopathy
and worsening of liver failure.6 From the early
period of surgical shunts, it has been known that a
calibrated shunt should be about 8–10 mm in
diameter, since larger (12–20 mm diameter) H-
graft shunts conferred no advantage over total end-
to-side portacaval shunts.6,7 Moreover, side-to-side
and H-graft shunts are known to effectively
decompress the liver by allowing retrograde flow
through the portal vein, so they are very effective at
controlling ascites. This is in contrast with end-to-
side portacaval shunts that decompress the liver by
decreasing portal perfusion but do not allowJournaretrograde portal flow. These were the premises
from which TIPS was developed8 and soon
demonstrated to be effective, feasible, and associ-
ated with low peri-operative mortality, to the point
that it has almost entirely replaced surgical portal-
systemic shunts.9
Since its introduction, TIPS technology has
improved dramatically, although there is still room
to optimise the procedure (Table 1). The most
important technical improvement for TIPS was the
introduction of polytetrafluoroethylene-covered
stents.10 These have practically abolished the
most common drawback of uncovered (metal)
stents: TIPS dysfunction due to proliferation of the
neo-intima that covers the stent shunt leading to
its progressive stenosis/occlusion, which called for
close monitoring and re-intervention in over 50%
of cases within 6–12 months.9,11 This form of TIPS
dysfunction was much more frequent than TIPS
thrombosis, which was common only in patients
with pro-coagulant conditions, typically Budd-
Chiari syndrome.12 An important point during
deployment of covered stents for TIPS is making
sure that the stent is long enough to extend about 2
cm into the portal vein (the uncovered part of the
stent), while crossing the intra-parenchymal tract,
and the entire length of the hepatic vein until its
opening into the inferior vena cava (covered part).
Failure to do so may result in TIPS dysfunction
owing to the development of stenosis at the
non-stented part of the hepatic vein.
Current challenges
Nowadays TIPS dysfunction is no longer a big issue.
Current efforts aim at further improving TIPS out-
comes, specifically, at decreasing the incidence ofl of Hepatology 2020 vol. - j 1–5
Table 1. Main types of stents for transjugular intrahepatic portosystemic shunt.
Type of stents Advantages Disadvantages
Self-expanding uncovered stents Easy deployment High incidence of
dysfunction
Covered stents (self-expanding) Not prone to dysfunction Can continue to expand if
under dilated
Controlled-expansion covered stents Expand only to pre-set
diameters (e.g. 6-8-10 mm)
Bare
vs.
Covered
Length
<12 mmHg
protection from ascites, an
bleeding
+ve effects
Fig. 1. Factors influencing the
application of TIPS. PCG, portoca
systemic shunt.
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Expert Opinionpost-TIPS hepatic encephalopathy and liver failure,
coming back to the question of how big a TIPS
should be to prevent rebleeding/ascites while be-
ing small enough not to favour hepatic encepha-
lopathy/liver failure? Unfortunately, the available
evidence in this regard is lacking and mostly comes
from observations in the era of uncovered stents.11
Factors influencing the fall in portal
pressure gradient after TIPS (Fig. 1)
Increasing stent diameter is the easiest way of
decreasing PCG when placing a TIPS. This is
because according to Poiseuille's Law, the most
important factor determining resistance (R) to flow
in a blood vessel is its radius (r)
quadquadquadquadquadquadquadquadR¼8 L×gr4
The other variables in the equation are blood
viscosity (g) (relatively stable in normal circum-
stances), and vessel length (L). Length is much less
important than diameter, since it increases resis-
tance in an arithmetic way, while resistance (and
therefore PCG) is inversely related to the radius at
the fourth power. This explains why “bended” C-
shaped TIPS (usually to a branch of the right portal
vein) are less effective than “straight” TIPS, since at
the bending zone the cross-sectional shape of the
stent-TIPS is not circumferential but elliptical Type of stent
 Self expanding
vs.
Controlled expansion
Diameter Shape
Straight vs. bended
 PCG after TIPS
d 
<10 mmHg
 risk of encephalopathy, and
 risk of liver failure
-ve effects
effects of TIPS on the PCG. Considerations for the clinical
val pressure gradient; TIPS, transjugular intrahepatic porto-
Journal of Hepatology 2020 vol. - j(smaller compared to a circular shunt), leading to a
much higher resistance and PCG. Therefore,
straight, “central” TIPS between the main right
hepatic vein and the right portal vein are more
effective at decreasing the PCG than peripheral
shunts (Fig. 1).
How much shall we decrease the PCG to
prevent/correct complications of portal
hypertension?
Do we still need to decrease PCG to <12 mmHg or
by more than 50%?
Studies have shown that PCG should be decreased
to 12 mmHg or below,11 or by over 50% of baseline
(which in most cases means a PCG <12 mmHg)9 to
prevent the complications of portal hypertension.
This comes from careful observations showing that
recurrent bleeding and ascites occurred almost
exclusively when patients had a PCG of at least
12 mmHg after TIPS. Accordingly, it was recom-
mended to dilate the stent shunt until PCG was
<−12 mmHg. This seems simple, but it is not, since
first, PCG should be measured correctly, between
the portal vein and the inferior vena cava (not
between the portal vein and the right atrium, as
most interventional radiologists used to do).13
Since the right atrial pressure is always lower
than the inferior vena cava pressure, the porta-
atrial gradient overestimates the PCG, which may
lead to excessive stent dilatation. Second, sedation
and/or anaesthesia for TIPS frequently precludes
correct measurements of the PCG,14 which requires
post-TIPS measurements after the effects of
anaesthesia are gone or the day after,15 increasing
the burden and cost of TIPS, as well as requiring
interventional radiologists to recognise that accu-
rate haemodynamic measurements rather than
radiological images should guide their decisions.
Moreover, when using general anaesthesia, much
care should be given to avoid hypotension, which
prevents accurate measurements of portal pressure
gradient14 and may potentiate the reduction in
liver perfusion and contribute to post-TIPS liver
failure.
How small should TIPS diameter be to
avoid hepatic encephalopathy?
What is a beneficial fall in PCG after TIPS using
current improved stents?
A large proportion of patients developing severe
encephalopathy after TIPS have quite low PCG
(5–10 mmHg), suggesting a very narrow thera-
peutic window: below 12 mmHg to be effective,
above 10 mmHg to decrease the likelihood of en-
cephalopathy.11 In practice, this target may be
difficult to reach. Indeed, clinical practice is to
dilate the TIPS until achieving an effective reduc-
tion in portal pressure. In case of a gradual dilata-
tion, if – for instance – the PCG drops to 13 mmHg
after dilating the stent to 8 mm, it is likely that
after dilating to 10 mm the final PCG might be too1–5
low (say 6–7 mmHg). In this case the patient
should be carefully observed for encephalopathy
and post-TIPS worsening of liver failure, receive
early treatment with lactulose and rifaximin, and if
severe encephalopathy/deterioration of liver func-
tion occurs, a “TIPS reduction” should be planned.
This procedure requires co-axial re-stenting with a
covered stent of smaller diameter16 (and some-
times placement of a parallel [“tandem”], shorter,
external stent that is dilated to compress the TIPS
until the PCG reaches “safe” values).
It is important to note that most studies on
haemodynamic targets were done before the
introduction of covered stents and have not been
adequately updated since then. Why does this
matter? Uncovered stents, as mentioned above,
predictably tend to decrease in diameter over time,
so the decrease in PCG achieved after TIPS is not
sustained, but progressively lost over time until re-
intervention (TIPS angioplasty or re-stenting).11 In
contrast, with TIPS using covered stents, the pres-
sure drop is maintained during follow-up.10 It is
conceivable therefore that when using uncovered
stents, a greater (possibly excessive) PCG reduction
was required to maintain the PCG <−12 mmHg over
time. In other words, it is likely that covered stents
of lower diameter (causing a smaller fall in PCG)
could be as effective as larger uncovered stents.
This might in part explain the discrepancy between
a “good haemodynamic response” to pharmaco-
logical therapy (a decrease in hepatic venous
pressure gradient of at least 20% from baseline or
below 12 mmHg)17 and a good response to TIPS (a
50% decrease in PCG or to values <−12 mmHg).
11 At
this point, it is worth remembering that what is a
good haemodynamic response to covered TIPS has
not been adequately studied, since most studies
used the same PCG targets as for uncovered TIPS.
To further complicate these issues, several
studies indicate that self-expandable stents may
continue to dilate until achieving their nominal
diameter.18,19 This means that if the PCG is 11
mmHg after dilating a 10 mm stent to only 8 mm,
the stent may continue to self-dilate until reaching
approximately 10 mm in diameter, leading to a
further decrease in PCG and an increased risk of
encephalopathy. How frequently this spontaneous
expansion is clinically relevant is a matter of
debate, but certainly represents a limitation. This
led to a further technical improvement, the
“controlled-expansion” stents, that cannot spon-
taneously dilate over pre-set limits (controlled by
an external sheath).16,20
The bottom line is that with these technical
improvements, it is now feasible to perform a
calibrated shunt that will maintain its diameter
over time. However, we are still very far from
perfection, since we do not have an answer for
simple questions such as how large the shunt
should be, or what PCG reduction should be tar-
geted to prevent recurrent bleeding or ascites?JournaCertainly, the target PCG reduction should probably
be less than that required in the uncovered stent
era, but specific data to guide evidence-based
decisions are lacking.
Regarding the risk of developing hepatic en-
cephalopathy and post-TIPS worsening of liver fail-
ure we are also in uncertain territory. From the
experience with H-graft calibrated shunts we know
that 8mmshuntswere significantly better than large
shunts (12 mm and above).6,21 For TIPS, it has
recently been reported that under-dilated covered
TIPS (dilated toup to6–7mmindiameter)maycause
less encephalopathy than “standard” diameter TIPS
(8–10mmindiameter),22 but this is basedona single
non-randomised retrospective study with a rate of
overt hepatic encephalopathy of 54% at 1-year with
standard TIPS (in the upper reported range) and of
26.9% with under-dilated TIPS. Moreover, the study
reported no spontaneous dilation of the self-
expandable stents, which contrasts with the results
of studies conducted over longer observation
times.18 Better results could probably be achieved
with controlled-expansion stents. Based on the
limited data available, the best “small diameter” TIPS
to prevent or minimise the incidence of encepha-
lopathy, while effectively preventing rebleeding
and/or ascites, should be about 6–8 mm, but a “one-
size-fits-all” strategy is most likely unrealistic.21,23
Similarly, it is unknown whether other parameters
linked to outcomes in cirrhosis, such as age, quanti-
tative liver function tests, liver/spleen stiffness or
volume, heart function, inflammation, bacterial
translocation and malnutrition/sarcopenia, may be
factored into a decision-making algorithm that bal-
ances between keeping the shunt as small as
possible while sufficiently reducing PCG. An addi-
tional advantage of using small diameter TIPS is that
it may decrease the incidence of post-TIPS heart
failure.24 Small diameter TIPS would likely also
diminish the risk of aggravating liver failure after
TIPS. In most cases this is mild and transient, grad-
ually fading within 3 weeks of the TIPS procedure,
and is most likely related to a reduction of effective
liver perfusion with portal blood, which can be
aggravated by hypotension during the procedure.
Radiation hepatitis may be a potential concern in
difficult/long procedures.
What else can we do to prevent post-TIPS
encephalopathy? Expert
recommendations
Is there any further improvement that we could
introduce? Challenging aspects are summarised
in Box 1. Reported haemodynamic targets are
currently too narrow to be achieved in most cases,
and perhaps not entirely adequate nowadays, as
they were mostly obtained in the pre-covered stent
era. I hypothesise that what required a PCG
reduction to below 12 mmHg or >50% of baseline
using uncovered stents could be achieved with a
PCG decrease to say 14 mmHg or >30% of baseline.l of Hepatology 2020 vol. - j 1–5 3
Box 1. Challenging aspects in TIPS.
Pending questions:
• Do we still need to decrease PCG <12 mmHg or by more than 50%?
• What defines a beneficial fall in PCG after TIPS using current improved stents? 
 - we rely on old data!
Answers:
a. Less can be more: use small diameter TIPS (6-8 mm diameter) even if final PCG   
slightly above 12 mmHg
  - less HE doesn’t need to be matched by more bleeding/ascites
 - may decrease the incidence of heart failure after TIPS
b. Optimize the benefit of the decrease in PCG
 - by associating drugs
 - by associating procedures 
 -by life-style intervention and other
HE, hepatic encephalopathy; PCG, portacaval pressure gradient; TIPS, transjugular intrahepatic
portosystemic shunt.
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tients with small diameter TIPS that are likely to
result in less worsening of portal-systemic shunt-
ing and hence a lower likelihood of severe en-
cephalopathy and post-TIPS liver failure.20,21,23 Of
note, in high-risk situations, such as refractory as-
cites, the recent EASL guidelines already recom-
mended small diameter TIPS, although not
suggesting TIPS as small as 6 mm.25
According to this hypothesis, studies should
assess the effectiveness of small diameter TIPS (of
6 mm [or 7 mm] in diameter) complemented by
either drug therapy, an associated procedure, or
both, with the aim of reducing PCG by 30% of
baseline or to <−14mmHg. The goalwould be to avoid
an additional stent dilation (to 8–10 mm) that may
cause the portal pressure gradient to decrease too
much, hence increasing the risk of encephalopathy,
liver failure and/or heart failure. This would require
availability of controlled-expansion covered stents
of 6 mm initial diameter (expandable to 8 mm),
reserving 8 mm stents (expandable to 10 mm) for
patients with poor TIPS alignment.
Complementing a small diameter TIPS with
drugs
We first studied this some years ago and found that
an “insufficient” fall in PCG after TIPS (which may
occur even with fully expanded stents) can be
converted into a “satisfactory” one by adding pro-
pranolol, even at relatively low doses.26 Why? Very
schematically, because of the synergistic effect of
combining two different mechanisms to decrease
PCG: TIPS decreases the PCG by bypassing liver
resistance to portal flow, while propranolol de-
creases PCG by reducing splanchnic blood flow. In
addition to our published experience, we (among
others) have successfully used this approach
clinically with good results.26Journal of Hepatology 2020 vol. - jComplementing a small diameter TIPS with
associated procedures
I am referring here primarily to something that is
common practice in many centres and consists of
embolising collaterals that remain wide open after
TIPS. After using a small diameter TIPS to reach afinal
PCG of about 14 mmHg, occlusion/embolisation of
large collaterals feeding the varices has the potential
to notonly increaseefficacy (for instance, occlusionof
the left gastric veindramatically decreasesbloodflow
to oesophageal varices), but also to decrease the
likelihood of severe encephalopathy.27 This can be
particularly valuable in patients that cannot tolerate
or are poor candidates for non-selective beta-
blockers due to hypotension, the presence of relative
contra-indications or associated conditions.
Optimising the candidate for TIPS
It is worth noting that post-TIPS encephalopathy is a
complex condition that is not only determined
by TIPS diameter but by a myriad of non-
haemodynamic factors. Age, degree of liver and
kidney failure, chronic inflammation, urease-
producing intestinal bacteria, bacterial trans-
location and malnutrition/sarcopenia, are other
very important factors that can modulate the ther-
apeutic effort.3 Several of them are associated not
only with post-TIPS encephalopathy, but also with
post-TIPS survival.3 Administration of rifaximin,
started before TIPS, was shown to be effective in a
recent randomised controlled trial,28 leading to a
40% reduction in cases of hepatic encephalopathy.
Pre-habilitation (e.g. improving malnutrition before
TIPS) and rehabilitation (e.g. adding supervised
moderate exercise to nutrition after TIPS) could be
extremely important. Finally, a strict follow-up of
patients undergoing TIPS for refractory ascites en-
ables the need for diuretics to be tailored to avoid
dehydration, a relatively frequent cause of enceph-
alopathy 1–3 weeks after TIPS. Carefully explaining
avoidable triggers and warning signs (e.g. dehydra-
tion, constipation, hypoglycaemia in diabetics, early
identification of bacterial infection, including peri-
odontitis) to patients and their relatives is manda-
tory before discharge.3 A combination of all these
strategies should be attempted to further improve
outcomes in this particular population.
What I would not recommend
The procedure that I do not recommend is splenic
artery embolisation, since its effects may be tran-
sient (if this is a proximal embolisation) and the
procedure may cause severe complications.29 A
similar or greater decrease in portal blood flow can
be much more safely achieved by administering
propranolol.
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